Treatment 10 min
Colon Cancer Treatment by Stage: Chemotherapy and Beyond
When chemo is needed after colon cancer surgery, 3 or 6 months, which tests (RAS, BRAF, MSI, HER2) matter with metastases, and when immunotherapy works.
Written and medically reviewed by
Dr. Tara EinullaevaMedical oncologist, 9 years in practice. Credentials · reviewed 16 October 2026
Drug treatment for colon cancer depends above all on the stage. In stage I, chemotherapy is usually not needed; in stage III it is given after surgery almost always; in stage II the decision depends on risk factors. In metastatic cancer, the regimen is chosen according to molecular tests on the tumour and which side of the bowel it started in.
Below I explain how this works, so that you understand the logic of your treatment plan and know what to ask your doctor. I am talking about cancer of the colon (the larger part of the large bowel). Rectal cancer is treated with its own logic, often including radiotherapy — that is a topic for a separate article.
What the treatment plan depends on
Your doctor relies on three groups of information:
- The TNM stage — how deeply the tumour has grown into the bowel wall (T), how many lymph nodes are involved (N) and whether there are distant metastases (M). I explain how to read these letters in my article on TNM cancer staging.
- The pathology report after surgery — the tumour grade, invasion of blood vessels and nerves, how many lymph nodes were removed and examined, and whether the resection margins are clear.
- The molecular features of the tumour — first of all MSI/dMMR status (microsatellite instability / deficient DNA mismatch repair), and with metastases also RAS, BRAF and HER2.
Stages I and II: when chemotherapy isn't needed and when it's discussed
Stage I. The main treatment is surgery. Chemotherapy is usually not needed afterwards.
Stage II. The tumour has grown deep into the bowel wall, but the lymph nodes are not involved. For many people surgery alone is enough. Chemotherapy is discussed if there are signs of a high risk of recurrence. According to the American Cancer Society, these include:
- high tumour grade (a poorly differentiated tumour);
- a T4 tumour — one that has grown through the bowel wall or into nearby organs;
- tumour growth into blood or lymph vessels;
- fewer than 12 lymph nodes examined;
- tumour at the resection margin;
- bowel obstruction or perforation (a hole in the bowel wall) before surgery.
In stage II, MSI status must be checked. If the tumour is MSI-H/dMMR, its outlook is usually better, and chemotherapy with fluoropyrimidines (5-fluorouracil or capecitabine) is generally not given in this situation. If there is a high risk and no MSI, the usual options are 5-fluorouracil or capecitabine, sometimes combined with oxaliplatin.
To be honest: in stage II, experts still disagree on who really needs chemotherapy. That is why it is especially worth going through with your doctor which risk factors you have and what treatment would add in your situation.
Stage III: chemotherapy after surgery, and the question of 3 vs 6 months
In stage III the lymph nodes are involved, and the standard is surgery followed by adjuvant (post-operative) chemotherapy. I describe in detail why it is needed and how it differs from treatment before surgery in my article on treatment before and after surgery.
One of two oxaliplatin-based regimens is most often used:
- FOLFOX — drips of oxaliplatin and 5-fluorouracil;
- CAPOX (also called XELOX) — an oxaliplatin drip plus capecitabine tablets taken at home.
Some patients — depending on age and general health — receive a fluoropyrimidine alone, without oxaliplatin.
Six months of chemotherapy used to be the standard. The international IDEA analysis pooled 6 trials and almost 13,000 patients with stage III cancer to test whether treatment could be shortened to 3 months. The results:
| Group | What the IDEA analysis showed |
|---|---|
| Low risk (T1–T3 and N1) | A short course suits many patients; 3 months of CAPOX is a common choice |
| High risk (T4 and/or N2) | The benefit of a short course is less clear; 6 months is more often discussed |
| CAPOX regimen | 3 months was not inferior to 6 for overall survival |
| FOLFOX regimen | 6 months gave a small but significant advantage in disease-free survival |
| Grade 2 or higher neuropathy | 16% with 3 months vs 44.5% with 6 months |
Why this matters so much: oxaliplatin causes peripheral neuropathy — numbness, tingling and reduced sensation in the fingers and toes. The longer the treatment, the more common it is and the longer it may last after chemotherapy ends. Shortening the course where it is safe to do so directly affects quality of life after treatment.
Don’t stop or shorten chemotherapy on your own, even if you feel well. The length is chosen according to the stage and regimen, and only your treating doctor can change it — for example, if neuropathy is getting worse.
Metastatic cancer: which tests are needed before treatment starts
In stage IV, treatment is chosen according to the tumour’s molecular profile. Under the Russian national clinical guidelines and the Russian Society of Clinical Oncology (RUSSCO) guidelines, once distant metastases are found the tumour is tested for:
- KRAS and NRAS mutations (together — RAS);
- a BRAF mutation (with its type stated, above all V600E);
- MSI/dMMR — by PCR or immunohistochemistry;
- HER2 — overexpression or amplification.
Other tests are added in particular situations. For example, before fluoropyrimidines are given, the doctor may consider testing the DPYD gene: with some of its variants the body clears the drug more slowly and the risk of severe toxicity is higher.
What these results give you:
- RAS and BRAF without mutations — make it possible to add anti-EGFR antibodies (cetuximab or panitumumab) to chemotherapy. With a RAS mutation these drugs generally don’t work.
- BRAF V600E — for this mutation there is a combination of a BRAF inhibitor with an anti-EGFR antibody, sometimes together with chemotherapy.
- A HER2-positive tumour (without RAS and BRAF mutations) — anti-HER2 drugs are possible.
- MSI-H/dMMR — the main candidate for immunotherapy (more on this below).
For more on what targeted drugs are and what material the test is done on, see my article on targeted therapy.
Why it matters which side of the bowel the tumour is on
Patients are often surprised that the doctor wants to know exactly where the primary tumour was. The dividing line is the splenic flexure of the colon: tumours before it are right-sided, those after it (the descending and sigmoid colon) are left-sided.
These tumours differ biologically and respond differently to treatment. If the metastases cannot be removed, the Russian guidelines limit anti-EGFR antibodies to left-sided tumours — without RAS and BRAF mutations, without HER2 overexpression and without MSI. For right-sided tumours, chemotherapy combined with bevacizumab is preferred (an anti-angiogenic, anti-VEGF antibody that stops the tumour building blood vessels). Bevacizumab can be given regardless of RAS and BRAF status and of the side of the tumour.
The backbone of treatment is the same chemotherapy regimens: FOLFOX, FOLFIRI (with irinotecan), CAPOX and, for some patients in good general health, the more intensive FOLFOXIRI. If one regimen stops working, the next line is used.
Immunotherapy for MSI-H/dMMR
In about 5% of patients with metastatic colorectal cancer, the tumour is MSI-H/dMMR. For them, immunotherapy has changed the approach.
In the KEYNOTE-177 trial, patients with metastatic MSI-H/dMMR cancer received either pembrolizumab or chemotherapy as first-line treatment. The median time without progression was 16.5 months versus 8.2 months. Severe treatment-related side effects occurred in 22% on immunotherapy and 66% on chemotherapy. Immunotherapy is now a standard first-line option for these patients.
Immunotherapy has side effects too, but they differ from those of chemo: the immune system can attack the body’s own organs. If you are offered immunotherapy, discuss with your doctor which symptoms mean you should call straight away.
Liver metastases that can be removed
Liver metastases do not always mean lifelong chemotherapy. If there are only a few and the surgeon can remove them completely, surgery becomes part of treatment aimed at cure.
According to the RUSSCO guidelines, it usually looks like this:
- Metastases that can be removed straight away. They are removed, followed by FOLFOX or CAPOX chemotherapy — 6 months in total. High-risk patients may receive part of the course before surgery and part after. Adding targeted antibodies to chemotherapy is not recommended in this situation.
- “Potentially resectable” metastases. Intensive chemotherapy is given first to shrink the lesions; after 4–6 cycles the team assesses whether surgery is possible. The total length of treatment, including the pre-operative part, is about 6 months.
Whether the metastases can be removed is decided by a liver surgeon together with the oncologist and radiologist. If no such surgeon has looked at your scans, that is a reason to ask for their opinion.
Questions to ask your treating doctor
- What is my TNM stage, and which risk factors were found in the pathology report?
- Was my MSI/dMMR status tested? And with metastases — RAS, BRAF and HER2?
- Which chemotherapy regimen do you suggest, and for how long — 3 or 6 months? Why?
- What should I do if my fingers start to feel numb?
- Which side of the bowel was the tumour on, and how does that affect the choice of drugs?
- If there are liver metastases, has a surgeon assessed whether they can be removed?
If you were diagnosed recently and it’s unclear whether all the necessary tests have been done and why this particular regimen was chosen, I can review your records in a consultation and help you put together questions for your treating doctor.
Sources
- Treatment of Colon Cancer, by Stage — American Cancer Society, 2026
- Targeted Drug Therapy for Colorectal Cancer — American Cancer Society, 2026
- Practical guidelines for drug treatment of colon, rectosigmoid and rectal cancer — Russian Society of Clinical Oncology (RUSSCO), 2023
- Clinical guidelines “Cancer of the colon and rectosigmoid junction” — Ministry of Health of the Russian Federation, 2025
- Final Overall Survival Results of the IDEA Collaboration: 3 vs 6 Months of Adjuvant Chemotherapy for Stage III Colon Cancer — The ASCO Post, 2021
- Pembrolizumab Doubles Progression-Free Survival in MSI-H/dMMR Metastatic Colorectal Cancer — The ASCO Post, 2020
Frequently asked questions
This article is for information only and does not replace a consultation with your treating doctor. Decisions about tests and treatment are made by the doctor who looks after you.
